Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bone Mineral Density in HIV Switch to Dolutegravir + Rilpivirine
NCT02478632Phase 3Completed
- Sponsor
- ViiV Healthcare
- Start
- Jun 2015
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 3 trial of dolutegravir, rilpivirine in human immunodeficiency virus infection (HIV), sponsored by ViiV Healthcare. Started Jun 2015; status: completed.
02
Drugs
dolutegravirrilpivirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02478632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02478632.